JAK2-IN-20
JAK2-IN-20 is an orally active dual inhibitor targeting JAK2 kinase (IC50=49.17 nM) and influenza A virus PB2 protein (IC50=3.337 μM, Kd=2.82 μM). JAK2-IN-20 effectively blocks the JAK/STAT signaling pathway by reducing the phosphorylation levels of STAT1 and STAT3, thereby inhibiting viral replication and downregulating the expression of viral NP and PB2 proteins. In addition, JAK2-IN-20 significantly inhibits the mRNA expression of key inflammatory cytokines such as IL-6, TNF-α and IFN-β in inflammation and influenza infection models. JAK2-IN-20 serves as an important tool molecule for the study of influenza A virus infection and related pathologies.
For research use only. We do not sell to patients.
- Formula: C16H17F2N5O
- Molecular Weight:333.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
JAK2 49.17 nM (IC50) |
In Vitro
JAK2-IN-20 (compound 4B) potently protects MDCK cells against damage induced by H1N1 influenza virus (EC50=14.71 nM) and inhibits the cap-binding activity of influenza A PB2 protein (IC50=3.337 nM)[1].
JAK2-IN-20 exhibits low cytotoxicity in multiple cell lines, with a CC50 of >100 μM (48 h) in MDCK cells[1].
JAK2-IN-20 (1 μM; 60 min; 37°C) exhibits excellent metabolic stability in mouse liver microsomes, with a half-life of 47.8 min and an intrinsic clearance (CLint) of 29.0 μL/min/mg[1].
JAK2-IN-20 (250-2000 nM) binds directly to the cap-binding domain of influenza A virus PB2, with a Kd value of 2.82 μM[1].
JAK2-IN-20 (5-10 μM; 30 min; 6 h) dose-dependently inhibits LPS (1 μg/mL)-induced expression of pro-inflammatory cytokines (IL-6, IL-1β) and IFN-β in RAW 264.7 macrophages, and exhibits potent activity at 10 μM[1].
JAK2-IN-20 (5-10 μM; 30 min; 6 h) potently inhibits the expression of poly (I:C)-induced proinflammatory cytokines (IL-6, TNF-α) and type I interferons (IFN-α, IFN-β) in RAW 264.7 macrophages at a concentration of 10 μM[1].
JAK2-IN-20 (250-500 nM; 24 h) inhibits the expression of H1N1 virus PB2 mRNA and reduces the levels of virus-induced proinflammatory cytokines (IL-6, TNF-α) in A549 cells at a concentration of 500 nM[1].
JAK2-IN-20 inhibits the JAK/STAT signaling pathway in both H1N1-infected A549 cells and IFN-β-stimulated THP-1 cells by reducing the phosphorylation levels of STAT1 and STAT3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-induced RAW 264.7 macrophages
-
Concentration:5 μM, 10 μM
-
Incubation Time:30 min pre-LPS stimulation; 6 h post-stimulation
-
Result:Reduced LPS-induced IL-6 mRNA levels by 1.5-fold, IL-1β mRNA levels by 6.3-fold, and IFN-β mRNA levels by 83% at 10 μM.
Reduced IFN-β mRNA levels by 55% at 5 μM, with attenuated effects on IL-6 and IL-1β.
-
Cell Line:Poly(I:C)-induced RAW 264.7 macrophages
-
Concentration:5 μM, 10 μM
-
Incubation Time:30 min pre-poly(I:C) stimulation; 6 h post-stimulation
-
Result:Reduced poly(I:C)-induced IL-6 mRNA levels by 4.8-fold, TNF-α mRNA levels by 3.0-fold, IFN-β mRNA levels by 44-fold, and IFN-α mRNA levels by 1.8-fold at 10 μM.
-
Cell Line:H1N1-induced A549 cells
-
Concentration:250 nM, 500 nM
-
Incubation Time:24 h (added 1-2 h post-H1N1 infection)
-
Result:Reduced H1N1-induced PB2 mRNA expression by 67%, IL-6 mRNA levels by 5.2-fold, and TNF-α mRNA levels by 2.5-fold at 500 nM, with moderate inhibition of IFN-α and IFN-β.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1[1]
-
Dosage:3 mg/kg (i.v.); 30 mg/kg (p.o.)
-
Administration:i.v.; single dose; p.o.; single dose
-
Result:Achieved a Cmax of 1903 ng/mL, AUC0-t of 751 h ng/mL, T1/2 of 0.505 h, MRT0-t of 0.293 h, Vz of 2929 mL/kg, and Cl of 4011 mL/h/kg following intravenous administration.
Achieved a Cmax of 3513 ng/mL, AUC0-t of 7422 h ng/mL, T1/2 of 1.44 h, MRT0-t of 1.56 h, and oral bioavailability of 99.4% following oral administration.
Chemical Information
-
Molecular Weight 333.34
-
Formula C16H17F2N5O
-
SMILES
FC1=CC(C(C2=NC(N[C@@H](C)C(C)(C)O)=C(F)C=N2)=CN3)=C3N=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)